According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

Oncologic and complication rates generally favored the minimally invasive approach to inguinal lymph node dissection in penile cancer surgery. Minimally invasive approaches to inguinal lymph node ...

Adequate lymph node yield for patients with papillary thyroid cancer is associated with longer operations, longer hospitalization, and higher risk of recurrent laryngeal nerve injury and hypocalcemia, ...

On the basis of National Comprehensive Cancer Network guidelines, clinical stage (CS) II seminoma is treated with radiotherapy or chemotherapy. Primary retroperitoneal lymph node dissection (RPLND) ...

Purpose The long-term toxicities of chemotherapy and radiotherapy can represent a significant burden to testicular cancer survivors. Retroperitoneal lymph node dissection (RPLND) is an established ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...

For years, surgery for patients with stage III melanoma - melanoma that has spread to the lymph nodes - involved removing those lymph nodes along with the primary tumor. Known as completion lymph node ...

The role of pelvic lymph node dissection (PLND) in patients with localized prostate cancer remains controversial. Although guidelines are increasingly recommending extended PLND alongside radical ...

Study finds lower mortality rates associated with excisions of higher numbers of lymph nodes in patients with intermediate- and high-risk prostate cancer. Removal of greater numbers of lymph nodes ...

A single-center, randomized controlled trial conducted by researchers from Taiwan has shown that patients with gastric cancer who undergo extensive, D3 lymph-node dissection have higher survival rates ...

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Patients who underwent ...